A study of 153 melanoma and sarcoma patients undergoing immune checkpoint blockade (ICB) therapy has revealed a correlation between social vulnerability and gut microbiome composition, but not with overall survival, researchers reported this week. The findings, published in AJMC, suggest that while disadvantaged social circumstances are linked to less diverse and potentially less beneficial gut bacteria, this does not automatically translate to poorer patient outcomes in this specific treatment context.
Researchers assessed clinicopathologic data, dietary fiber intake, and gut microbiome profiles of patients treated with ICB, a type of cancer therapy that boosts the body’s immune system to fight tumors. The study utilized a Social Vulnerability Index (SVI) to quantify patients’ socioeconomic disadvantages. The median SVI percentile among the cohort was 0.4, with a range spanning 0.2 to 0.7. Median daily dietary fiber intake was 17 grams.
The analysis showed an inverse correlation between SVI and dietary fiber intake (r = -0.18, p = .0398), indicating that patients facing greater social vulnerability tended to consume less fiber. Gut microbiome analysis revealed that higher SVI scores were associated with reduced alpha diversity – a measure of the variety of microbial species – and lower levels of Bifidobacterium longum, a bacterium often considered beneficial. Conversely, increased fiber intake correlated with positive changes in the microbiome, including increased alpha diversity and abundance of favorable bacteria.
Notably, the study did not find a statistically significant difference in overall survival between patients with high and low SVIs. Patients with higher SVIs had not reached a median overall survival time at the study’s conclusion, compared to 81.7 months for those with lower SVIs. Although, a clear survival advantage was observed among patients with higher dietary fiber intake, with a median overall survival of 58.9 months compared to those who had not reached a median survival time.
These findings align with previous research highlighting the potential of dietary fiber to improve outcomes in cancer patients undergoing ICB. A separate study, published in PubMed, also found a link between increased dietary fiber and improved outcomes in patients receiving ICB. Researchers are now investigating the mechanisms by which dietary fiber influences the gut microbiome and, the effectiveness of ICB therapy.
Longitudinal microbiome profiling of 175 melanoma patients undergoing ICB, detailed in a recent Nature publication, further underscores the dynamic relationship between the gut microbiome and treatment response. That study identified specific microbial species-level genome bins (SGBs) that differed between patients achieving prolonged progression-free survival (PFS) and those with shorter PFS durations, with some SGBs exhibiting changes only at baseline and others only after treatment initiation. The researchers found that a log ratio of certain SGBs correlated with overall survival.
The current study’s authors conclude that while social vulnerability is associated with an unfavorable gut microbiome composition, it does not independently predict worse overall survival in melanoma and sarcoma patients treated with ICB. They emphasize that dietary fiber intake represents a potentially modifiable pathway to improve outcomes, particularly for those with increased social vulnerability. Further research is needed to determine optimal dietary interventions and to understand the complex interplay between social factors, the gut microbiome, and cancer treatment efficacy.
Leave a Reply